Molecular Diagnostics and Treatment of Pancreatic Cancer

  • ID: 2784423
  • Book
  • 458 Pages
  • Elsevier Science and Technology
1 of 4

Molecular Diagnostics and Treatment of Pancreatic Cancer describes the different emerging applications of systems biology and how it is shaping modern pancreatic cancer research. This book begins by introducing the current state of the art knowledge, trends in diagnostics, progress in disease model systems as well as new treatment and palliative care strategies in pancreatic cancer. Specific sections are dedicated to enlighten the readers to newer discoveries that have emerged from gene expression profiling, proteomics, metabolomics and systems level analyses of pancreatic cancer datasets. First of a kind and novel network strategies to understand oncogenic Kras signaling in pancreatic tumors are presented. The attempts to computationally model and prioritize microRNAs that cause pancreatic cancer resistance are also highlighted.

Addressing this important area, Molecular Diagnostics and Treatment of Pancreatic Cancer provides insights into important network evaluation methodologies related to pancreatic cancer related microRNAs targetome. There are dedicated chapters on critical aspects of the evolving yet controversial field of pancreatic cancer stems cells. The work concludes by discussing the applications of network sciences in pancreatic cancer drug discovery and clinical trial design.

  • Encompasses discussion of innovative tools including expression signatures in cell lines, 3D models, animal xenograft models, primary models and patient derived samples, aiding subversion of traditional biology paradigms, and enhancing comprehension across conventional length and temporal scales
  • Coverage includes novel applications in targeted drugs, polypharmacology, network pharmacology and other related drug development arenas - helping researchers in pancreatic cancer drug discovery
  • Summarizes many relevant computational and clinical references from fast-evolving literature
  • Comprehensive glossary helps newer readers understand technical terms and specialized nomenclature
Note: Product cover images may vary from those shown
2 of 4
  1. An Integrated Systems Approach to the Study of Pancreatic Cancer
  2. Systems Biology of Pancreatic Cancer: The Role of Tumor-Microenvironment Communication in Development, Progression and Therapy Resistance
  3. Proteomics of Pancreatic Cancer Stem Cells
  4. Systems and Network Guided Pancreatic Cancer Drugs
  5. Prioritizing Pancreatic Cancer Related miRNAs Using Systems Platform
  6. Pancreatic Proteome Guided Biomarker Discovery
  7. Proteomic Analysis of Pancreatic Biopsies
  8. RNAi Screen in Pancreatic Cancer Drug Development
  9. Modeling Apoptotic Signaling in Pancreatic Cancer
  10. Genetic, Epigenetic, and Proteomic Evaluation Post Laser Microdissection of Pancreatic Tumors
  11. Proteomic Analysis of Gemcitabine Toxicity
  12. Understanding Pancreatic Cancer through Proteomics of Stellate Cells in Rat Models
  13. Genome Wide CpG Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas
  14. Proteomic Profiling of Archival Lesions in Pancreatic Cancer
  15. Computational Assessment of Benign and Potentially Malignant Pancreatic Cysts
  16. Pancreatic Cancer Pharmacogenomics
  17. Systems Biology on Pancreatic Splice Variants
  18. Systems and Network for Pancreatic Cancer Drug Discovery
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Azmi, Asfar
Dr. Asfar S. Azmi, PhD. is an Assistant Professor in the Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan USA. He has more than a decade of research experience in the area of cancer biology and drug discovery. His translational work broadly focuses on designing, developing and testing novel small molecule drugs in a wide variety of solid tumors and hematological malignancies. His research has a special focus on oncogenic KRAS driven tumors, particularly pancreatic ductal adenocarcinoma.

Dr. Azmi utilizes cutting edge computational biology in his drug discovery work that has helped in bringing a number of agent into the clinic such as AT-101 (an advanced Bcl-2 inhibitor currently in 23 different clinical trials) and nuclear export inhibitor (Selinexor). Dr. Azmi has published over 100 peer reviewed articles and numerous editorials as well. He served as executive guest editor for 5 different thematic issues in prestigious journals such as Seminars in Cancer Biology and others. He is the editor of a book on Systems Biology in Cancer Research and Drug Discovery for Springer and another book on Molecular Diagnostics and Treatment of Pancreatic Cancer published through Elsevier Academic Press. He is the editor in Chief of Wolters Kluwer Journal Oncobiology and Targets. In summary, Dr. Azmi has proven track record of comprehensive editorial work. He brings with him vast experience necessary to undertake this important project and complete it in a timely fashion.

Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown